MMP2 and breast carcinoma: SPP1-R3 aptamer was used to inactivate SPP1 and disturb surface binding of SPP1 to its cell surface CD44 receptor and mediators of ECM degradation, MMP-2, in human breast cancer cells (Mi et al., 2009).